IBIO_OUT_1 [2025-04-28 11:30:24 -0400] 5256 Bytes | 1416 tokens | Cum: 1416 tkns (17.70% of 8k)
==========================================================================

Booyah, my friends! It's already 11:30 AM on Mon Apr 28, 2025, and I've got my eyes locked on iBio (IBIO), pushing up to $1.19 from $0.9190. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: iBio (IBIO)
IPO: 2008-08-19 (16 Years Ago)
Market Cap: $11,849,611
Shares Outstanding: 9,880,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Here’s a list of headlines for iBio:

Apr-22-25 08:00AM - iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Apr-07-25 07:00AM - iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Apr-01-25 10:00AM - iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025
Feb-19-25 04:05PM - iBio to Begin Trading on the Nasdaq Stock Exchange
Feb-17-25 04:38PM - Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?
Feb-10-25 04:05PM - iBio Reports Fiscal Second Quarter 2025 Financial Results
Jan-13-25 07:00AM - iBio Announces New Investments from Board Members and Officers
Jan-07-25 07:00AM - iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Jan-03-25 07:58AM - iBio Expands Pipeline with New Antibody Agreement
Jan-02-25 09:24AM - Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform
Jan-02-25 09:24AM 07:00AM - iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
Nov-25-24 08:00AM - iBio Strengthens Board with Appointment of Two New Independent Directors
Nov-12-24 04:05PM - iBio Reports Fiscal First Quarter 2025 Financial Results
Oct-10-24 08:00AM - iBio and AstralBio Provide Update on Myostatin Program for Obesity
Sep-20-24 04:05PM - iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Sep-03-24 07:00AM - iBio to Participate in Upcoming Investor Conferences
Aug-12-24 04:30PM - iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
Jun-03-24 07:00AM - iBio Closes Sale of Manufacturing Facility in Texas
May-13-24 04:05PM - iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Apr-05-24 02:35PM - 3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
Mar-27-24 07:00AM - iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
Mar-26-24 07:35PM - iBio Announces $15.0 Million Private Placement

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-02T12:00:00Z - iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio
B2 - 2024-10-14T14:58:00Z - Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments
B3 - 2024-09-03T11:00:00Z - iBio to Participate in Upcoming Investor Conferences
B4 - 2024-06-03T11:00:00Z - iBio Closes Sale of Manufacturing Facility in Texas
B5 - 2024-05-13T20:05:00Z - iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
B6 - 2024-03-28T10:52:00Z - Balancing Volatility With Stability When Trading Penny Stocks

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for iBio (IBIO).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

IBIO_OUT_3 [2025-04-28 11:30:25 -0400] 957 Bytes | 260 tokens | Cum: 1678 tkns (20.97% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/02/3003451/0/en/iBio-Expands-Cardiometabolic-and-Obesity-Program-with-Anti-Myostatin-Antibody-Discovered-Using-its-Proprietary-Platform-In-Licensed-from-AstralBio.htmliBio has in-licensed a potentially best-in-class long-acting anti-myostatin antibody from AstralBio and is launching a new program featuring a myostatin + activin A bispecific antibody designed to promote weight loss, prevent muscle loss and weight regain.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_5 [2025-04-28 11:30:26 -0400] 982 Bytes | 299 tokens | Cum: 1979 tkns (24.74% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T13:31:24Z - Troops arrest 23 suspected oil thieves, recover 180,000 litres of stolen products...
A2 - 2025-04-28T13:13:53Z - Troops foil theft, arrest 23 suspects, recover 180,000 litres of oil products | The Guardian Nigeria...
A3 - 2025-04-24T18:19:50Z - Merck (MRK) Q1 2025 Earnings Call Transcript | The Motley Fool...
A4 - 2025-04-22T17:05:43Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Akso Health (NASDAQ:AHG), Adagio Medica...
A5 - 2025-04-22T12:06:53Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Gelteq (NASDAQ:GELS), iBio (NASDAQ:IB...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

IBIO_OUT_7 [2025-04-28 11:30:26 -0400] 1181 Bytes | 313 tokens | Cum: 2294 tkns (28.68% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Troops arrest 23 suspected oil thieves, recover 180,000 litres of stolen products**Date: 2025-04-28Source: {'uri': 'thenationonlineng.net', 'dataType': 'news', 'title': 'Latest Nigeria News, Nigerian Newspapers, Politics'}URL: https://thenationonlineng.net/troops-arrest-23-suspected-oil-thieves-recover-180000-litres-of-stolen-products/Troops of 6 Division, Nigerian Army (NA) in partnership with other security agencies have arrested 23 suspected oil thieves and confiscated 180,000 stolen products across the Niger Delta region.

Confirming the development in Port Harcourt on Monday, the acting deputy director, 6 Division Army Public Relations, Lt. Col. Danjuma Jonah Danjuma, said the troops destroyed 13 illegal refineries in the region.

Danjuma said in Rivers State, around Orachi/Okolomade general area in Abua/Odual Local Government Area (LGA), the troops confiscated over 45,000 lit

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_9 [2025-04-28 11:30:27 -0400] 1181 Bytes | 275 tokens | Cum: 2571 tkns (32.14% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): res of illegally refined Automotive Gasoline Oil (AGO) in sacks, concealed at different locations in the forest.

He said the operatives destroyed an active illegal refining site around Obiafo in Ogba/Egbema/Ndoni LGA (ONELGA) and recovered over 28,000 litres of stolen crude in two reservoirs.

Danjuma confirmed that one suspect was arrested in the area while others fled on sighting troops, saying an 800-meter-long hose and a pumping machine were recovered.

He said the troops conducted an operation around Peterside Community in Bonny LGA, where an illegal refining site was uncovered, with three pots and receivers and over 10,000 litres of stolen products recovered.

He said: "Similarly, in a snap operation conducted along Obrikom -- Omoku, two wooden boats conveying over 3,000 litres of illegally refined AGO were intercepted.

"Meanwhile, seven suspected oil thieves were apprehended in

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_11 [2025-04-28 11:30:28 -0400] 1181 Bytes | 274 tokens | Cum: 2847 tkns (35.59% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): connection with the heinous crime. The ongoing clearance operations at the fringes of the Imo River are progressing with several illegal refining sites, drum pots, and receivers taken out."

In Akwa Ibom State, Danjuma said following credible intelligence, troops intercepted a tanker truck with registration number 1430 LA filled with 39,994 litres of stolen products along the Itu - Calabar highway in Itu LGA.

He said two suspected oil thieves were arrested in connection with the seizure, adding that an investigation led to the discovery of fake waybill papers possessing criminal elements.

He said a similar operation was also conducted along Abak-Ikomima road in Uyo LGA and led to the interception of a truck with registration number 22689 LA laden with 39,985 litres of stolen crude.

Read Also: Troops arrest 23 oil thieves, seize 67,000 litres of stolen products in Niger Delta

"The pro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_13 [2025-04-28 11:30:29 -0400] 1181 Bytes | 301 tokens | Cum: 3150 tkns (39.38% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): ducts were also said to be conveyed with fake papers. Closely related was a sting operation conducted at Ibio Ndot Community in Orok Anam LGA, where troops discovered 103 nylon bags filled with over 3,090 litres of illegally refined AGO concealed in a Cassava farm", he said.

Danjuma said that in Bayelsa State, around Biseni in Yenagoa Local Government Area (YELGA), troops discovered an illegal refining site with over 2,600 litres of AGO in sacks.

He said that in the Adibawa area, also in YELGA, over 2,500 litres of stolen crude and 1,100 litres of illegally refined AGO in sacks were recovered.

"Also, recovered were eight wheelbarrows used for the illicit activities. This was in addition to six suspected oil thieves arrested at the scene", he said.

He quoted the General Officer Commanding, 6 Division, Nigerian Army, Maj.-Gen. Emmanuel Eric Emekah, calling on troops to sustain the pres

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_15 [2025-04-28 11:30:30 -0400] 336 Bytes | 94 tokens | Cum: 3246 tkns (40.58% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): sure on all forms of economic sabotage in the region.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_17 [2025-04-28 11:30:31 -0400] 1136 Bytes | 320 tokens | Cum: 3568 tkns (44.60% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-22 8-K Item 1.01. Entry Into a Material Definitive Agrmt.

Exclusive License Agrmt

On April 21, 2025, iBio, Inc. (the Company), entered into an exclusive agreement (the License Agrmt) with AstralBio, Inc. (AstralBio), pursuant to which AstralBio has licensed to the Compan...

S2 - 2025-04-08 8-K Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the Company) has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Curr Report on Form 8-K.

The information in this Item 7.01 and in the corporate presentati...

S3 - 2025-04-07 8-K Item 7.01. Regulation FD Disclosure.

On April 7, 2025, iBio, Inc., (the Company) issued a press release announcing data from a non-human primate study of IBIO-600, the Companys long-acting anti-myostatin antibody, and preclinical data of a first-in-class Activin E antibody. A c...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

IBIO_OUT_19 [2025-04-28 11:30:32 -0400] 1181 Bytes | 269 tokens | Cum: 3839 tkns (47.99% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item 1.01. Entry Into a Material Definitive Agreement.

Exclusive License Agreement

On April 21, 2025, iBio, Inc. (the Company), entered into an exclusive agreement (the License Agreement) with AstralBio, Inc. (AstralBio), pursuant to which AstralBio has licensed to the Company, on an worldwide exclusive basis and with the right to grant sublicenses, under the AstralBio Licensed Patents and AstralBio Licensed Know-How to Develop, Manufacture and Commercialize and otherwise exploit any product directed to activin E that contains the licensed antibody targeting activin E for research, diagnosis, treatment, prevention, or management of any disease or medical condition (the Licensed Product). All capitalized terms herein have the definitions assigned to them in the License Agreement unless otherwise defined herein.

The Company will be solely responsible for all decisions related to t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_21 [2025-04-28 11:30:33 -0400] 1181 Bytes | 260 tokens | Cum: 4101 tkns (51.26% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): he launch, sales and marketing and promotion of the Licensed Products in its discretion, subject to the terms of the License Agreement, and for all costs for all activities related to, the Development, Manufacture and Commercialization of the Licensed Product worldwide. In consideration for the rights and licenses granted by AstralBio to the Company in the License Agreement, the Company has agreed to pay AstralBio (i) an upfront license fee in the amount of $750,000 within thirty days after the effective date of the License Agreement, which the Company will pay by the application u of a credit provided by AstralBio to it in the same amount and (ii) upon the occurrence of specified developmental and commercial milestones, milestone payments of up to a total of $28 million, which can be paid by cash or, provided the Company remains listed on Nasdaq Capital Market or another national stock

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_23 [2025-04-28 11:30:33 -0400] 1181 Bytes | 263 tokens | Cum: 4366 tkns (54.57% of 8k)
==========================================================================

Showing S1 (chunk 3 of 5): exchange at the time of the payment, the Company issuing shares of its Common Stock, subject to the Exchange rules, and provided, however, in no event shall the Company issue to AstralBio pursuant to the License Agreement resulting in AstralBio owning more than 19.9% of the total number of shares of Common Stock of the Company as of the date of entering into the License Agreement. In the event the Company sublicenses the Licensed Product or a product that includes the Licensed Product, the Company will pay AstralBio a sublicense fee, which fee is a range of a low to mid-single-digit percentage based on the proceeds of the sublicense fees to a third party.

The License Agreement will remain in effect at all times and thereafter, unless and until terminated earlier pursuant to the License Agreement. The License Agreement can be terminated (i) by the Company for any reason or no reason upon

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_25 [2025-04-28 11:30:34 -0400] 1181 Bytes | 259 tokens | Cum: 4627 tkns (57.84% of 8k)
==========================================================================

Showing S1 (chunk 4 of 5): 45 days written notice to AstralBio (ii) by either party upon written notice to the other party if the other party materially breaches the License Agreement and such breach is not cured to the reasonable satisfaction of the non-breaching party within 90 days of receipt of such written notice (iii) by either party upon certain bankruptcy or insolvency events of the other party and (iv) by AstralBio if the Company or any sublicensee challenges the patentability, enforceability or validity of any claim related to any AstralBio Licensed Patent or the secret and substantial nature of any AstralBio Licensed Know-How, subject to certain exceptions as set forth in the License Agreement.

The Licensed Product was identified by AstralBio using the Companys proprietary technology stack and was designed for subcutaneous administration with the potential for an extended half-life.

The foregoing des

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_27 [2025-04-28 11:30:35 -0400] 802 Bytes | 182 tokens | Cum: 4811 tkns (60.14% of 8k)
==========================================================================

Showing S1 (chunk 5 of 5): criptions of the License Agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in the License Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

IBIO_OUT_29 [2025-04-28 11:30:44 -0400] 6266 Bytes | 1711 tokens | Cum: 6526 tkns (81.58% of 8k)
==========================================================================

This is our set of metrics for iBio.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 774,461 | Perf Month: -74.12% | Option/Short: No / Yes | Sales Y/Y TTM: 650.00% |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 783.13K | Perf Quarter: -61.70% | Short Float: 9.94% | ROE: -123.28% |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 3.23 | Index: - | Short Ratio: 1.18 | ROI: -113.63% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 30.38 | Market Cap: 11.26M | Short Interest: 0.93M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.33 | Shs Outstand: 9.87M | Beta: 1.24 | EPS Surprise: -4.35% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -34.48% | Shs Float: 9.31M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -67.79% | Inst Own: 26.65% | Sales past 5Y: -18.92% | Earnings: Feb 10 BMO |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -57.82% | Insider Own: 5.67% | Employees: 19 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: 34.61% | Insider Trans: 75.54% | Debt/Eq: 0.30 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by iBio officers or majority shareholders (if available).

Inside Trans: iBio, Inc. (IBIO) by Brenner Martin (See Remarks) on 2025-02-21
- Stock Option (right to buy): 230700 shares at $0 (D)

Inside Trans: iBio, Inc. (IBIO) by Duran Felipe (Chief Financial Officer) on 2025-02-21
- Stock Option (right to buy): 84700 shares at $0 (D)

Inside Trans: iBio, Inc. (IBIO) by Banjak Marc (Chief Legal Officer) on 2025-02-21
- Stock Option (right to buy): 71000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 375000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -19303000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.17
Average Volume: 1231749.5
30-Day High: 4.12
30-Day Low: 0.7

[Detailed Financials: Q2 2025]
- Total Assets: $21,697,000.00
- Total Liabilities: $7,802,000.00
- Total Equity: $13,895,000.00
- Current Assets: $8,285,000.00
- Current Liabilities: $4,709,000.00

[Income Statement: Q2 2025]
- Revenue: $200,000.00
- Net Income: $-4,364,000.00
- Gross Profit: N/A
- Operating Income: $-4,419,000.00
- Earnings Per Share (EPS): -0.48

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-4,023,000.00

[Detailed Financials: Q1 2025]
- Total Assets: $24,517,000.00
- Total Liabilities: $6,763,000.00
- Total Equity: $17,754,000.00
- Current Assets: $11,705,000.00
- Current Liabilities: $3,469,000.00

[Income Statement: Q1 2025]
- Revenue: $0.00
- Net Income: $-3,989,000.00
- Gross Profit: N/A
- Operating Income: $-4,106,000.00
- Earnings Per Share (EPS): -0.46

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-3,164,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of iBio (IBIO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about iBio.

2) MARKET_SCORE[]
This conversation was initiated because IBIO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for IBIO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, IBIO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect IBIO to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of iBio.

11) ETHICAL_RATING[]
Rate iBio’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of iBio.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

IBIO_IN_31 [2025-04-28 11:30:44 -0400] 126 Bytes | 29 tokens | Cum: 6774 tkns (84.67% of 8k)
==========================================================================

====================================
[2025-04-28 11:30:44] # Analysis Completed
Elapsed Time: 20.97 seconds